0.66Open0.64Pre Close19 Volume315 Open Interest25.00Strike Price983.00Turnover9031.28%IV5.22%PremiumJan 17, 2025Expiry Date0.31Intrinsic Value100Multiplier-2DDays to Expiry1.29Extrinsic Value100Contract SizeAmericanOptions Type-0.5623Delta0.2480Gamma15.43Leverage Ratio-1733.3224Theta0.0000Rho-8.68Eff Leverage0.0001Vega
Calavo Growers Stock Discussion
Fiscal Year 2024 Financial Overview
• Total net sales increased 11.4% to $661.5 million from the prior year
◦ Grown segment net sales increased 13.3% to $597.6 million
◦ Prepared segment net sales decreased 4.2% to $63.9 million
• Total gross profit increased 8.3% to $67.8 million from the prior year
◦ Grown segment gross profit increased 9.4% to $55.3 million
◦ Prepared segment gross profit increased 3.8% to $12.5 million
• Net income from continuing oper...
Gapping up
$Eli Lilly and Co (LLY.US)$ shares rose 2% after a panel of FDA advisors recommended the approval of its Alzheimer's drug known as donanemab.
$General Motors (GM.US)$ The automaker's stock added more than 1% after its board authorized a $6 billion stock buyback program.
$Shopify (SHOP.US)$ The e-commerce stock rose about 1% after JPMorgan initiated coverage with an overweight rating, stating that the recen...
A GameStop $GameStop (GME.US)$ director just made the first open-market stock purchase this year, while the CEOs of department-store chain Kohl’s $Kohl's Corp (KSS.US)$ and avocado slinger Calavo Growers CVGW $Calavo Growers (CVGW.US)$ picked up millions of dollars of stock.
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
No comment yet